ERCC1-low patients exhibited a significantly better overall response rate (73.7% vs 15.4%) and improved disease control (94.7% vs 61.5%) than did ERCC1-high patients, consistent with findings from patients with head-and-neck squamous cell, esophageal, and bladder cancers.[22–24] Furthermore, low ERCC1 expression was associated with significantly longer PFS and OS. This evidence concerns the gene ERCC1 and urinary bladder cancer.